CORDIS
EU research results

CORDIS

English EN

Systems Biology to Identify Molecular Targets for Vascular Disease Treatment

Project information

Grant agreement ID: 603288

Status

Closed project

  • Start date

    1 February 2014

  • End date

    31 January 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 350 348,27

  • EU contribution

    € 5 976 413

Coordinated by:

MEDIZINISCHE UNIVERSITAT GRAZ

Austria

Objective

Asymptomatic vascular damage accumulates for years before patients are identified and subjected to therapeutic measures. The limited knowledge on early vascular disease pathophysiology is reflected in the lack of therapeutic options. SysVasc aims to overcome this limitation by mounting a comprehensive systems medicine approach to elucidate pathological mechanisms, which will yield molecular targets for therapeutic intervention.
The consortium is based on established multidisciplinary European research networks, including specialists in pre-clinical and clinical research, omics technologies, and systems biology from research intensive SMEs and academia; partners synergistically provide access to an extensive number of selected population-based cohorts and associated datasets, cutting edge modeling and simulation methods, and established cardiovascular disease (CVD) animal models and patient cohorts. The coordinated application of these tools and know-how will identify pathophysiological mechanisms and key molecules responsible for onset and progression of CVD and validate their potential to serve as molecular targets for therapeutic intervention. To this end, the consortium will also use unique resources to evaluate molecular homology between the available model systems and human disease, which will yield reliable essential preclinical research tools to explore proof of concepts for therapeutic intervention studies and ultimately translate relevant results into novel therapeutic approaches.
Collectively, SysVasc will identify and validate novel biology-driven key molecular targets for CVD treatment. Major scientific, societal and economic impact is expected including, but not limited to, providing a valuable resource to further CVD research, and enhance competitiveness of participating SMEs and European health industry in general by translating knowledge into “innovative services” in therapeutic target and drug research.

Coordinator

MEDIZINISCHE UNIVERSITAT GRAZ

Address

Auenbruggerplatz 2
8036 Graz

Austria

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 483 025,08

Administrative Contact

Burkert Pieske (Prof.)

Participants (18)

MOSAIQUES DIAGNOSTICS GMBH

Germany

EU Contribution

€ 883 600

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 400 407

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 789 166

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 378 560

BAKER HEART AND DIABETES INSTITUTE

Australia

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 257 060,40

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 250 124,40

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Greece

EU Contribution

€ 222 160

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 239 564

SIB INSTITUT SUISSE DE BIOINFORMATIQUE

Switzerland

EU Contribution

€ 390 080

UNIVERSITY OF BRITISH COLUMBIA

Canada

BIOCRATES LIFE SCIENCES AG

Austria

EU Contribution

€ 342 130

EAGLE GENOMICS LIMITED

United Kingdom

EU Contribution

€ 317 296,50

GENOMIC INVESTMENTS BV

Netherlands

BIOLUTION GMBH

Austria

EU Contribution

€ 76 184

UNIVERSITY OF PLYMOUTH

United Kingdom

EU Contribution

€ 339 648

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 396 447,62

GenomeScan B.V.

Netherlands

EU Contribution

€ 210 960

Project information

Grant agreement ID: 603288

Status

Closed project

  • Start date

    1 February 2014

  • End date

    31 January 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 350 348,27

  • EU contribution

    € 5 976 413

Coordinated by:

MEDIZINISCHE UNIVERSITAT GRAZ

Austria